The long-term research focus of my laboratory is to develop new imaging and therapeutic agents and nanomaterials that could contribute immensely to detection, treatment, and prevention of cancer and related diseases. Along that direction, we will continue to develop necessary chemistry and bioconjugate techniques for important cellular and molecular targets for clinical translation to improve patient-specific diagnosis and treatment option. In addition to radiopharmaceutical based SPECT and PET imaging agents, our research projects are directed to develop contrast agents for MR, fluorescence, CT and photoacoustic imaging modalities. Recent projects are also directed to develop radiotheranostics for targeted radionuclide therapy of advanced metastatic cancers.
Since 2006 my research work has been focused on developing new imaging and therapeutic agents targeting the prostate-specific membrane antigen (PSMA). We have generated extensive structure-activity relationships in that regard and has contributed to several important firsts in this area, namely the design rules and synthesis of the 1st radiometallated (2008), 1st successful in vivo optical (2009) and the 1st Gallium-68-labeled (2010), the 1st dual modality SPECT-optical (2011), the 1st gadolinium magnetic resonance imaging (MR) (2015) and the 1st Chemical-Exchange Saturation Transfer (CEST) MR (2018) PSMA-targeted probes. Our Ga-68/Lu-177-labeled theranostic agent is currently undergoing multi-center phase 1 trials sponsored by Advanced Accelerator Applications/Novartis.
View all on PubMed
Banerjee SR, Foss CA, Castanares M, Mease RC, Byun Y, Fox J, Hilton J, Lupold SE, Kozikowski AP, Pomper MG. Synthesis and evaluation of technetium-99m-and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA). J Med Chem. 2008;51:4504-4517
Banerjee SR, Pullambhatla M, Byun Y, Nimmagadda S, Green G, Fox JJ, Horti A, Mease RC, Pomper MG. Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer. J Med Chem. 2010;53:5333-5341
Banerjee SR, Pullambhatla M, Byun Y, Nimmagadda S, Foss CA, Green G, Fox JJ, Lupold SE, Mease RC, Pomper MG. Sequential SPECT and optical imaging of experimental models of prostate cancer with a dual modality inhibitor of the prostate-specific membrane antigen. Angew Chem Int Ed 2011; 50:9167-9170
Banerjee SR*, Minn I, Kumar V, Josefsson A, Lisok A, Brummet M, Chen J, Kiess AP, Baidoo K, Brayton C, Mease RC, Brechbiel M, Sgouros G, Hobbs RF, Pomper MG. Preclinical evaluation of Pb-labeled low-molecular-weight compounds for targeted radiopharmaceutical therapy of prostate cancer. J Nucl Med. 2019 (online)
Banerjee SR*, Kumar V, Lisok A, Chen J, Minn I, Brummet M, Boinapally S, Cole M, Ngen E, Wharram B, Brayton C, Hobbs R, Pomper MG. Lu-labeled low-molecular-weight agents for PSMA-targeted radiopharmaceutical therapy. Eur J Nucl Med Mol Imaging. 2019 (online)
Nuclear imaging and radiotherapeutics agents targeting carbonic anhydrase IX (second generation)
Patent # JHU C14017 | 2016
Prostate-specific membrane antigen targeted high-affinity agents for endo radiotherapy of prostate cancer.
Patent # JHU C14083 |
PSMA targeted reversed carbamates and methods of use thereof.
Patent # WO 2016065145 A2 20160428. | 2016
New scaffolds and multifunctional intermediates for imaging psma and cancer therapy.
Patent # WO 2016065142 A2 20160428. | 2016
Salicylic Acid-based Polymeric CEST Contrast agents for molecular imaging of prostate-specific membrane antigen.
Patent # C13062 | 2015
Prostate-specific Membrane Antigen Targeted Plasmon-enhanced Raman Spectroscopy Reporters for Molecular Imaging of Prostate Cancer.
Patent # JHU C13637 | 2015
Preparation of metal or radiometal-labeled urea- and carbamate-based PSMA inhibitors for PSMA-targeted imaging and radiotherapy.
Patent # WO 2015171792 A1 20151112 | 2015
PSMA-targeting compounds and uses thereof. United States Patent US2015/010438A
Patent # WO 2010108125 A2 20100923 | 2015
Azole heterocycles for MRI contrast and pH sensing.
Patent # WO 2014186737 A1 20141120 | 2014
Salicylic acid, salicylic acid analogs and anthranilic acid derivatives for MRI contrast.
Patent # WO 2014182538 A1 20141113. | 2014
Theranostic targeted nanoplexes which carry Multimodality imaging reporters together with target enzyme inhibitors, such as siRNAs and target prodrug enzymes, and their use in disease diagnosis and treatment.
Patent # US2014/0178399A1, WO 2012135592 A2 20121004 | 2014
New homomultivalentevd heteromultivalent inhibitors of prostate specific membrane antigen (PSMA)
Patent # WO 2013082338 A1 20130606 | 2013
PSMA-targeted nanoparticles for therapy of prostate cancer.
Patent # US2011/02006779 | 2009
Labeled inhibitors of prostate specific membrane antigen (PSMA), biological evaluation, and use as imaging agents
Patent # 9,044,468, WO2009/002529. | 2008